TrialCancer immunology, immunotherapy : CII2026
Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.
Ryusuke Murakami et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.